Health Care & Life Sciences » Pharmaceuticals | Harbin Gloria Pharmaceuticals Co. Ltd.

Harbin Gloria Pharmaceuticals Co. Ltd. A | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,287
1,880
2,662
2,930
2,986
5,392
Cost of Goods Sold (COGS) incl. D&A
321
746
1,059
1,306
964
1,470
Gross Income
967
1,134
1,603
1,624
2,021
3,922
SG&A Expense
779
614
713
693
1,489
3,413
EBIT
180
507
869
888
516
482
Unusual Expense
3
-
12
16
12
285
Non Operating Income/Expense
1
3
56
78
19
137
Interest Expense
-
28
88
111
170
175
Pretax Income
269
548
841
857
368
188
Income Tax
40
92
127
130
66
50
Equity in Affiliates
-
-
1
1
3
9
Consolidated Net Income
230
456
713
728
305
129
Net Income
227
444
677
717
310
126
Net Income After Extraordinaries
227
444
677
717
310
126
Net Income Available to Common
227
444
677
717
310
126
EPS (Basic)
0.11
0.21
0.31
0.33
0.14
0.06
Basic Shares Outstanding
2,100
2,113
2,199
2,198
2,198
2,198
EPS (Diluted)
0.11
0.21
0.31
0.33
0.14
0.06
Diluted Shares Outstanding
2,100
2,113
2,199
2,198
2,198
2,198
EBITDA
248
611
1,021
1,051
699
676
Other Operating Expense
8
14
21
44
16
28
Non-Operating Interest Income
22
12
12
12
15
22
Minority Interest Expense
3
12
36
12
4
3

About Harbin Gloria Pharmaceuticals Co.

View Profile
Address
No. 29 Beijing Road
Harbin Heilongjiang 150025
China
Employees -
Website http://www.gloria.cc
Updated 07/08/2019
Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research and development of biological products. It offers cardiovascular, cerebrovascular and skeletal muscular treatment, and antitumor and nutritional drugs. The company products include creatine phosphate sodium injections, clopidogrel bisulfate tablets, cerebroprotein hydrolysate injections, cervus and cucumis polypeptide injections, calcium levofolinate injections, and potassium and magnesium aspartate injections.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.